Determination of the HLA-DM interaction site on HLA-DR molecules

Immunity

Volumn 13, Issue 4, 2000, Pages 517-527

  Doebele, Robert C ^a,b   Busch, Robert ^b   Scott, Hyman M ^b   Pashine, Achal ^b   Mellins, Elizabeth D ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DM ANTIGEN; HLA DR ANTIGEN; HLA DR3 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; PROTEIN CLIP; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DROSOPHILA; EPSTEIN BARR VIRUS; HLA SYSTEM; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 0033713296     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)00051-0     Document Type: Article

References (48)

1. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides
2. Nomenclature for factors of the HLA system, 1995
3. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: Implications for assembly, maturation, and function
4. Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM
5. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain
6. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading
7. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules
8. Setting the standards: Quality control in the secretory pathway
9. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells
10. Crystal structure of mouse H2-M
11. Crystal structure of I-Ak in complex with a dominant epitope of lysozyme
12. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3
13. Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization
14. Differential expression and serologically distinct subpopulations of human la antigens detected with monoclonal antibodies to la alpha and beta chains
15. Characterization of polymorphism within the H2-M MHC class II loci
16. Site-directed mutagenesis by overlap extension using the polymerase chain reaction
17. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen
18. Direct demonstration of an HLA-DR allotypic determinant on the low molecular weight (beta) subunit using a mouse monoclonal antibody specific for DR3
19. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules
20. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DRI
21. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8
22. Editing of the HLA-DR-peptide repertoire by HLA-DM
23. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH
24. Two populations of la-like molecules on a human B cell line
25. Intracellular transport of class II MHC molecules directed by invariant chain
26. Cutting edge: A single, essential hydrogen bond controls the stability of peptide-MHC class II complexes
27. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes
28. A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex
29. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides
30. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules
31. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation
32. HLA class II regulation and structure. Analysis with HLA-DR3 and HLA-DP point mutants
33. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides
34. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding
35. A structural transition in class II major histocompatibility complex proteins at mildly acidic pH
36. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments
37. Association between HLA-DM and HLA-DR in vivo
38. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes
39. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II
40. Mediation by HLA-DM of dissociation of peptides from HLA-DR
41. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide
42. Interaction of murine MHC class I molecules with tapasin and TAP enhances peptide loading and involves the heavy chain alpha3 domain
43. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH
44. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs
45. HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion
46. Monoclonalanti-lamurine alloantibodies crossreactive with the la- homologues of other mammalian species including humans
47. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM